Ipca Laboratories Ltd.

IPCALAB

₹1286.0

2.23% (28.05)

Market Cap

₹32,588 Cr.

P/E

59.54

About

Established in 1949, IPCA Laboratories Limited is an integrated pharmaceutical company that manufactures and markets various formulations and APIs for different therapeutic segments. With a global pre… Read more

Established in 1949, IPCA Laboratories Limited is an integrated pharmaceutical company that ma… Read more

Low

849

52W Range

High

1374

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Forensics

8 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE

Latest

8.64%

3yr Average

10.96%

5yr Average

14.77%

Net Profit Margin

Latest

7.14%

3yr Average

10.0%

5yr Average

12.85%

ROCE

Latest

12.48%

3yr Average

14.25%

5yr Average

18.16%

Debt to Equity

Latest

0.22

3yr Average

0.2

5yr Average

0.16

Market Share

0.81 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

1.03 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

55.08 %

(as of Nov 21)

Historic

Anti-Malarial - Market Share

3.84 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.11 %

(as of Nov 21)

Historic

Blood Related - Market Share

2.09 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

1.20 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.12 %

(as of Nov 21)

Historic

Endocrinology - Market Share

1.02 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

1.11 %

(as of Nov 21)

Historic

Neurological - Market Share

0.55 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

8.06 %

(as of Nov 21)

Historic

Pain - Market Share

1.80 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

0.83 %

(as of Nov 21)

Historic

Respiratory - Market Share

0.39 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

2.23 %

(as of Nov 21)

Historic

Urology - Market Share

0.43 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up - Branded Generics

Location Wise Break-Up - Generics

Location Wise Break-Up - API

Location Wise Break-Up

Therapeutic Area Break-Up

Operational Metrics

US DMF Filings (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Suppliers

Bharat Dynamics Ltd.
Elgi Equipments Ltd.
Borosil Renewables Ltd.
GMM Pfaudler Ltd.
Gulshan Polyols Ltd.
TPL Plastech Ltd.
Iris Business Services Ltd.
Take Solutions Ltd.

Showing 5 of 8

FAQs on Ipca Laboratories Ltd. Business

What does Ipca Laboratories do?

IPCA Laboratories Limited is a pharmaceutical company founded in 1949, with a global presence in manufacturing and marketing various formulations and APIs across different therapeutic segments. It is a leading supplier of APIs worldwide.

Who are the competitors of Ipca Laboratories?

Ipca Laboratories major competitors are Gland Pharma, Ajanta Pharma, JB Chem & Pharma, Pfizer, Natco Pharma, Glenmark Pharma, Alembic Pharma.
Market Cap of Ipca Laboratories is ₹32,588 Crs.
While the median market cap of its peers are ₹29,269 Crs.

Is Ipca Laboratories financially stable compared to its peers?

Ipca Laboratories seems to be less financially stable compared to its peers.
Altman Z score of Ipca Laboratories is 6.15 and is ranked 7 out of its 8 competitors.

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Jun			Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec